tofacitinib产品活性：tofacitinib是 jak1/2/3 抑制剂，ic50 分别为1，20 和 112 nm。
研究领域：epigenetics | stem cell/wnt | jak/stat signaling
作用靶点：jak
in vitro: tofacitinib (cp-690550) citrate binds potentially at jak3 and jak2 as 2.2 nm and 5 nm (kd). the report includes additional binding for tofacitinib at camk1 (kd of 5,000 nm), dcamkl3 (kd of 4.5 nm), mst2 (kd of 4,300 nm), pkn1 (kd of 200 nm), rps6ka2 (kin.dom.2-c-terminal) (kd of 1,400 nm), rps6ka6 (kin.dom.2-c-terminal) (kd of 1,200 nm), snark (kd of 420 nm), tnk1 (kd of 640 nm) and tyk2 (kd of 620 nm).
in vivo: animals that are treated with tofacitinib show a significantly lower production of anti-drug antibodies (adas) compare with peg-treated control mice (for five weeks after initial immunization, p<0.01, n=8). moreover adas become detectable earliest on day 28. a difference of 1000- to 200-fold in titers to ss1p is apparent from days 21 through 35, respectively. compare to ss1p, mice injected with keyhole limpet hemocyanin (klh) generate a more rapid antibody response. yet, the administration of tofacitinib reduces anti-klh titers compare to controls (p<0.05 on day 21, p4 hours.
相关产品：fda-approved drug library plus | drug repurposing compound library | fda-approved drug library mini | kinase inhibitor library | jak/stat compound library | stem cell signaling compound library | fda-approved drug library | drug repurposing compound library plus | epigenetics compound library | bioactive compound library plus | ruxolitinib | baricitinib | upadacitinib | tofacitinib citrate | momelotinib | pacritinib | chz868 | azd-1480 | at9283 | filgotinib | wp1066 | itacitinib | sb1317 | cerdulatinib | tyk2-in-4 | gandotinib | cucurbitacin i | pyridone 6 | peficitinib | delgocitinib | solcitinib | rgb-286638 free base | atractylenolide i | pf-06651600 | cep-33779 | decernotinib | tg101209 | az960
MedChemExpress LLC
郑先生
86-021-58955995
17321200539